NCT00461981 - A Phase 2 Study to Evaluate Immune Responses of FluMist® | Biotech Hunter

Enrollment

101

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

December 31, 2007

Study Completion Date

February 29, 2008

Conditions

Influenza Vaccine

Interventions

BIOLOGICAL

TIV, Trivalent Inactivated Influenza Virus Vaccine

0.25 mL will be administered intramuscularly for each of two doses

BIOLOGICAL

FluMist, Influenza Virus Vaccine Live

0.5 mL will be administered intranasally (approximately 0.25 mL into each nostril) for each of two doses

Trial Locations (19)

13760

Regional Clinical Research, Inc., Endwell

22180

Advanced Pediatrics, Vienna

23454

Pediatrics at the Beach, Virginia Beach

33409

Palm Beach Research Center, West Palm Beach

40509

Central Kentucky Research Associates, Lexington

42303

Peak Medical Research, LLC, Owensboro

45040

Northeast Cincinnati Pediatric Asso., Inc., Mason

45406

Dayton Clinical Research, Dayton

68134

Meridian Clinical Research, LLC, Omaha

70006

Benchmark Research, Metairie

72205

Arkansas Pediatric Clinic, Little Rock

73401

Harvey Pediatrics, Jonesboro

75230

Allergy Immunology Research Center of North Texas, Dallas

78209

Healthcare Discoveries, Inc., San Antonio

78414

Celia Reyes-Acuna, M.D., Corpus Christi

84041

Wee Care Pediatrics, Layton

84405

Bear Care Pediatrics, Ogden

89015

Henderson Pediatrics, Henderson

92805

NuLife Clinical Research, Anaheim